Performance evaluation and clinical impact of the Oncomine Myeloid Research Assay for gene expression analysis in myeloid haematologic malignancies
- 23 August 2022
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 76 (11) , 778-783
Abstract
Aim: Gene expression analysis facilitates the detection of diagnostic and prognostic biomarkers for myeloid haematological malignancies. The Oncomine Myeloid Research Assay (OMA; Thermo Fisher Scientific, Massachusetts, USA) provides a comprehensive analysis of gene expression of five target genes, along with gene alteration and fusion. Here, we present the performance of the OMA for gene expression analysis. Methods: In total, 53 RNA samples from patients diagnosed with acute myeloid leukaemia (AML) or myelodysplastic syndrome were included. Of these 53 samples, 3 were evaluated for reproducibility and 50 were evaluated for comparison with RNA-sequencing (RNA-seq). The prognostic impact of the gene expression profile produced by both OMA and RNA-seq in AML was investigated using follow-up data from 33 patients with AML. Results: The OMA showed good intrarun and interrun reproducibility. Compared with the RNA-seq results, high correlations were found in BAALC, MECOM and WT1 (all r>0.9), with moderate correlations in MYC (r=0.75, pSMC1A (r=0.42, p=0.002). The agreement between OMA and RNA-seq in classifying the dysregulated expression group was almost perfect, except for SMC1A (κ=0.175). Among these five genes, only BAALC showed a significant clinical impact in patients with AML. Patients with high BAALC expression showed significantly shorter overall survival based on both OMA (p=0.037) and RNA-seq (p=0.003). Conclusions: OMA gene expression analysis offers reproducible and accurate gene expression data for most targeted genes and demonstrates the utility of BAALC expression as a prognostic marker in AML.Keywords
This publication has 25 references indexed in Scilit:
- The molecular pathogenesis of the myelodysplastic syndromesEuropean Journal of Haematology, 2015
- StringTie enables improved reconstruction of a transcriptome from RNA-seq readsNature Biotechnology, 2015
- Gene expression profiling in MDS and AML: potential and future avenuesLeukemia, 2011
- High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic AbnormalitiesJournal of Clinical Oncology, 2010
- A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospectsBlood, 2009
- High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimatedBlood, 2008
- Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal KaryotypeClinical Cancer Research, 2005
- BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyBlood, 2003
- Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2003
- TrueLeukemia, 1999